MODEL-BASED CALCULATION FOR EFFECTIVE CANCER RADIOIMMUNOTHERAPY

The major problem of tumour radioimmunotherapy remains the low tumour antibody uptake and this leads to inadequate tumour irradiation. The antibody characteristics which influence uptake have been identified and quantified previously using a non-linear compartmental model that simulates antibody distribution to tumour and body after intravenous injection. The model has now been extended, in combination with MIRD dosimetry tables, to calculate the integral tumour/body radiation dose for a range of antibody masses (1, 10 and 50 mg) sizes (binding site fragments and whole molecules) and affinities (K = 10(9)-10(13) mol(-1)). Antibody requirements for delivering 60 Gy to the tumour over 11.6 days were calculated for I-131 and Y-90-labelled antibodies and included the effect of widely varying dose rates. The model predicted that intact antibodies of high affinity (10(11)-10(13) mol(-1)) produced effective tumour radiation doses with acceptable whole body radiation levels. By contrast, antibody fragments gave higher body radiation levels and required larger injected activity because of renal excretion. The model predicted higher therapeutic indices for Y-90-labelled antibody compared with I-131.